Slovenia - Tiếng Slovenia - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sandoz d.d. - acetilsalicilna kislina, bisoprolol - kapsula, trda - acetilsalicilna kislina 100 mg / 1 kapsula; bisoprolol 8,48 mg / 1 kapsula - bisoprolol in acetilsalicilna kislina

Liên Minh Châu Âu - Tiếng Slovenia - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloksetin - anxiety disorders; diabetic neuropathies; depressive disorder, major - psychoanaleptics, - zdravljenje velike depresivne motnje. zdravljenje diabetične periferne nevropatske bolečine. zdravljenje splošne anksiozne motnje. cymbalta je navedeno v odrasli.

Liên Minh Châu Âu - Tiếng Slovenia - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloksetin - neuralgia; diabetic neuropathies; depressive disorder, major - psychoanaleptics, - duloxetine lilly je navedeno v odraslih za:zdravljenje hudih depresivnih disordertreatment za diabetično periferne nevropatske paintreatment od splošnih anksioznost disorderduloxetine lilly je navedeno v odrasli.

Liên Minh Châu Âu - Tiếng Slovenia - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloksetin hidroklorid - urinarna inkontinenca, stres - psychoanaleptics, - zdravilo yentreve je indicirano za ženske za zdravljenje zmerne do hude stalne urinske inkontinence (sui).

Liên Minh Châu Âu - Tiếng Slovenia - EMA (European Medicines Agency)

esteve pharmaceuticals, s.a. - duloksetin - anxiety disorders; depressive disorder, major; diabetic neuropathies - psychoanaleptics, - zdravljenje je huda depresivna motnja;zdravljenje diabetično periferne nevropatske bolečine;obravnava splošne anksiozne motnje;xeristar je navedeno v odrasli.

Slovenia - Tiếng Slovenia - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

krka, d.d., novo mesto - acetilsalicilna kislina - gastrorezistentna tableta - acetilsalicilna kislina 100 mg / 1 tableta - acetilsalicilna kislina

Slovenia - Tiếng Slovenia - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

krka, d.d., novo mesto - acetilsalicilna kislina - gastrorezistentna tableta - acetilsalicilna kislina 160 mg / 1 tableta - acetilsalicilna kislina

Slovenia - Tiếng Slovenia - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

krka, d.d., novo mesto - acetilsalicilna kislina - gastrorezistentna tableta - acetilsalicilna kislina 75 mg / 1 tableta - acetilsalicilna kislina

Liên Minh Châu Âu - Tiếng Slovenia - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloksetin - diabetične nevropatije - psychoanaleptics, - zdravljenje diabetične periferne nevropatske bolečine. ariclaim je navedeno v odrasli.

Liên Minh Châu Âu - Tiếng Slovenia - EMA (European Medicines Agency)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotična sredstva - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.